Hypertension in chronic kidney disease—treatment standard 2023
Nephrology Dialysis Transplantation · 30.11.2023 · 38 (12) · 2694-2703
DOI: 10.1093/ndt/gfad118 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 24.06.2023. Verfasst von Panagiotis I Georgianos und 1 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Hyperkalemia, Hypertension, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Hypertension is very common and remains often poorly controlled in patients with chronic kidney disease (CKD). Accurate blood pressure (BP) measurement is the essential first step in the diagnosis and management of hypertension. Dietary sodium restriction is often overlooked, but can improve BP control, especially among patients treated with an agent to block the renin–angiotensin system. In the presence of very high albuminuria, international guidelines consistently and strongly recommend the use of an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker as the antihypertensive agent of first choice. Long-acting dihydropyridine calcium channel blockers and diuretics are reasonable second- and third-line therapeutic options. For patients with treatment-resistant hypertension, guidelines recommend the addition of spironolactone to the baseline antihypertensive regimen. However, the associated risk of hyperkalemia restricts the broad utilization of spironolactone in patients with moderate-to-advanced CKD. Evidence from the CLICK (Chlorthalidone in Chronic Kidney Disease) trial indicates that the thiazide-like diuretic chlorthalidone is effective and serves as an alternative therapeutic opportunity for patients with stage 4 CKD and uncontrolled hypertension, including those with treatment-resistant hypertension. Chlorthalidone can also mitigate the risk of hyperkalemia to enable the concomitant use of spironolactone, but this combination requires careful monitoring of BP and kidney function for the prevention of adverse events. Emerging agents, such as the non-steroidal mineralocorticoid receptor antagonist ocedurenone, dual endothelin receptor antagonist aprocitentan and the aldosterone synthase inhibitor baxdrostat offer novel targets and strategies to control BP better. Larger and longer term clinical trials are needed to demonstrate the safety and efficacy of these novel therapies in the future. In this article, we review the current standards of treatment and discuss novel developments in pathophysiology, diagnosis, outcome prediction and management of hypertension in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA.
ORCID-Profile: Rajiv Agarwal
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Georgianos, P. I., & Agarwal, R. (2023). Hypertension in chronic kidney disease—treatment standard 2023. Nephrology Dialysis Transplantation, 38(12), 2694-2703. https://doi.org/10.1093/ndt/gfad118
Vancouver
Georgianos PI, Agarwal R. Hypertension in chronic kidney disease—treatment standard 2023. Nephrology Dialysis Transplantation. 2023;38(12):2694-2703. doi:10.1093/ndt/gfad118
BibTeX
@article{Georgianos2023,
author = {Georgianos, Panagiotis I and Agarwal, Rajiv},
title = {Hypertension in chronic kidney disease—treatment standard 2023},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {12},
pages = {2694--2703},
doi = {10.1093/ndt/gfad118}
}
EUVIMED